Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3070908

CC1CCN(c2ccccc2C(N)=O)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.55
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
GAA P10253 4/20 0.49
KMT2A Q03164 2/20 0.49
USP2 O75604 2/20 0.49
MEN1 O00255 1/20 0.49
HPGD P15428 1/20 0.44
KDM4E B2RXH2 2/20 0.44
POLB P06746 2/20 0.44
NR4A1 P22736 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
CTPS1 P17812 1/20 0.43
ACHE P22303 1/20 0.41
GFER P55789 1/20 0.41
CDK8 P49336 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29752319 0.90 NPC1 (0.66) NPC1ALDH1A1SMN1; SMN2GAAKMT2A
SCHEMBL3088803 0.90 NPC1 (0.66) NPC1ALDH1A1SMN1; SMN2GAAKMT2A
Trifluoroacetic Acid SCHEMBL3070914 0.84 GAA (0.72) NPC1ALDH1A1SMN1; SMN2GAAKMT2A
Trifluoroacetic Acid SCHEMBL5104669 0.83 NPC1 (0.79) NPC1ALDH1A1SMN1; SMN2GAAKMT2A
SCHEMBL6650052 0.80 KMT2A (0.60) NPC1ALDH1A1SMN1; SMN2GAAKMT2A
Trifluoroacetic Acid SCHEMBL3539634 0.78 CSF1R (0.46) ALDH1A1SMN1; SMN2GAAUSP2KDM4E
SCHEMBL2558795 0.77 NPC1 (0.64) NPC1SMN1; SMN2GAAKMT2AKDM4E
SCHEMBL3084334 0.77 NPC1 (0.68) NPC1ALDH1A1SMN1; SMN2GAAKMT2A
SCHEMBL2260505 0.77 NPC1 (0.68) NPC1ALDH1A1SMN1; SMN2GAAKMT2A
SCHEMBL8258317 0.77 KMT2A (0.56) NPC1ALDH1A1SMN1; SMN2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER NPC1 4368/4885ALDH1A1 4731/4885SMN1; SMN2 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.